 |
인쇄하기
취소
|
Handok tries to extend additional indications of Tracleer tab.
The indication of Tracleer tab., an anti pulmonary hypertension drug sold by Handok seems to extend to chronic thromboembolic pulmonary hypertension (CTEPH) based on the phase III clinical studies, Handok said on March 26.
Traclear tab. was originally developed by Actelion in Switzerland.
The CTEPH is a pulmonary hypertension disease caused by infarction, about 5,000 patients of which wer...
Traclear tab. was originally developed by Actelion in Switzerland.
The CTEPH is a pulmonary hypertension disease caused by infarction, about 5,000 patients of which wer...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.